 
        
        
        
                货号:A148043
                
                同义名:
                    
                        
                            
                                Dimebolin dihydrochloride; Dimebolin (hydrochloride)
                            
                        
                    
                
                
                
                    
                     
                
            
Latrepirdine dihydrochloride是一种神经活性化合物,对组胺能、α-肾上腺素能和 5-羟色胺能受体具有拮抗活性。Latrepirdine 刺激淀粉样前体蛋白 (APP) 的降解代谢和 β-淀粉样蛋白 (Aβ) 的分泌。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | 5-HT ↓ ↑ | 5-HT1 ↓ ↑ | 5-HT2 ↓ ↑ | 5-HT3 ↓ ↑ | 5-HT5 ↓ ↑ | 5-HT6 ↓ ↑ | 5-HT7 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Desvenlafaxine | ++ 5-HT, Ki: 40.2 nM | 98% | |||||||||||||||||
| Lamotrigine | + 5-HT (rat brain synaptosomes), IC50: 474 μM 5-HT (human platelets), IC50: 240 μM | 98% | |||||||||||||||||
| Venlafaxine | ✔ | 99% | |||||||||||||||||
| Fluvoxamine maleate | ✔ | 99% | |||||||||||||||||
| Iloperidone | ✔ | 99% | |||||||||||||||||
| Ziprasidone HCl | ✔ | 98+% | |||||||||||||||||
| Atomoxetine HCI | + 5-HT, Ki: 77 nM | 98% | |||||||||||||||||
| Dapoxetine HCl | ✔ | 97% | |||||||||||||||||
| Trazodone | ✔ | 98+% | |||||||||||||||||
| Clomipramine HCl | ✔ | 98% | |||||||||||||||||
| Mirtazapine | ✔ | 99+% | |||||||||||||||||
| Escitalopram oxalate | +++ 5-HT, Ki: 0.89 nM | 97% | |||||||||||||||||
| Duloxetine | ✔ | 97% | |||||||||||||||||
| Sertraline HCl | ++ 5-HT, Ki: 13 nM | 98% | |||||||||||||||||
| Citalopram HBr | +++ serotonin reuptake, IC50: 1.8 nM | 98% | |||||||||||||||||
| Latrepirdine 2HCl | ✔ | GluR | 99% | ||||||||||||||||
| Fluoxetine HCl | ✔ | 99.5% | |||||||||||||||||
| Paroxetine HCl | ✔ | AChR | 99% | ||||||||||||||||
| BMY 7378 | ++ 5-HT1D, pIC50: 5.9 5-HT1A, pIC50: 6.4 | + 5-HT2, pIC50: 5.5 | 97% | ||||||||||||||||
| Flibanserin | +++ 5-HT1A, Ki: 1 nM | + 5-HT2A, Ki: 49 nM | 95% | ||||||||||||||||
| LY310762 | + 5-HT1D, Ki: 249 nM | 99%+ | |||||||||||||||||
| Cyclobenzaprine HCI | ✔ | 99% | |||||||||||||||||
| Blonanserin | +++ 5-HT2, Ki: 3.98 nM | 99% | |||||||||||||||||
| Cyproheptadine HCl | ++++ 5-HT2, IC50: 0.6 nM | 99+% | |||||||||||||||||
| Olanzapine | ✔ | 99+% | |||||||||||||||||
| Pimavanserin hemitartrate | +++ 5-HT2A, pIC50: 8.7 | 99% | |||||||||||||||||
| Ketanserin | +++ 5-HT2C (Rat), Ki: 50 nM 5-HT2C (Human), Ki: 2.5 nM | 99%+ | |||||||||||||||||
| Loxapine succinate | ++ 5-HT2 (human), Ki: 6.8 nM 5-HT2 (bovine), Ki: 6.6 nM | 98% | |||||||||||||||||
| Agomelatine | ✔ | 98% | |||||||||||||||||
| Clozapine | ✔ | 98% | |||||||||||||||||
| Amitriptyline | + 5-HT2, Ki: 235 nM | SERT | 99% | ||||||||||||||||
| PRX-08066 maleate | +++ 5-HT2B, IC50: 3.4 nM | 98+% | |||||||||||||||||
| RS-127445 | ++++ 5-HT2B, pIC50: 10.4 5-HT2B, pKi: 9.5 | 99%+ | |||||||||||||||||
| Sarpogrelate HCl | ++++ 5-HT2A, Kd: 2.1 nM 5-HT2C, Kd: 1.1 nM | 98% | |||||||||||||||||
| Tropisetron | ✔ | 99% | |||||||||||||||||
| Ramosetron HCl | ++++ 5-HT3 receptor, Ki: 0.091 nM | 98% | |||||||||||||||||
| Ondansetron | ✔ | 99% | |||||||||||||||||
| Granisetron | ✔ | 98% | |||||||||||||||||
| Alosetron HCl | ✔ | 98% | |||||||||||||||||
| Ondansetron HCl dihydrate | ✔ | 98% | |||||||||||||||||
| VUF10166 | ++++ 5-HT3AB, Ki: 22 nM 5-HT3A, Ki: 0.04 nM | 99%+ | |||||||||||||||||
| Azasetron HCl | ++++ 5-HT3, IC50: 0.33 nM | 99% | |||||||||||||||||
| Asenapine maleate | +++ 5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6 | ++++ 5-HT2C, pKi: 10.46 5-HT2A, pKi: 9.75 | +++ 5-HT5A, pKi: 8.84 | ++++ 5-HT6, pKi: 9.6 | ++++ 5-HT7, pKi: 9.94 | 97% | |||||||||||||
| Risperidone | ++ 5-HT1B, Ki: 14.9 nM 5-HT1D, Ki: 84.6 nM | ++++ 5-HT2A, Ki: 61.9 nM 5-HT2C, Ki: 12 nM | + 5-HT5A, Ki: 206 nM | ++ 5-HT7, Ki: 6.6 nM | 98% | ||||||||||||||
| SB 271046 HCl | +++ 5-HT6, pKi: 8.92 | 99%+ | |||||||||||||||||
| Intepirdine | ++++ 5-HT6, pKi: 9.63 | 99%+ | |||||||||||||||||
| SB-269970 HCl | ++ 5-HT7, pKi: 8.3 | 98+% | |||||||||||||||||
| BRL 15572 | ++ 5-HT1D, pKi: 6 5-HT1B, pKi: 6.1 | ++ 5-HT2A, pKi: 6.6 5-HT2B, pKi: 6.2 | + 5-HT6, pKi: 5.9 | + 5-HT7, pKi: 6.3 | 95% | ||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | AMPK ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WZ4003 | ++++ NUAK2, IC50: 100 nM NUAK1, IC50: 20 nM | 98+% | |||||||||||||||||
| Dorsomorphin | ++ AMPK, Ki: 109 nM | 99% | |||||||||||||||||
| HTH-01-015 | +++ NUAK1 , IC50: 100 nM | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | H1 receptor ↓ ↑ | H2 receptor ↓ ↑ | H3 receptor ↓ ↑ | H4 receptor ↓ ↑ | Histamine receptor ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydroxyzine 2HCl | 99+% | ||||||||||||||||||
| Cyclizine | ✔ | 97% | |||||||||||||||||
| Loratadine | + B(0)AT2, IC50: 4 μM | 98% | |||||||||||||||||
| Desloratadine | ++ Histamine H1 receptor, IC50: 51 nM | 98% | |||||||||||||||||
| Doxylamine succinate | ✔ | 99% | |||||||||||||||||
| Ebastine | ✔ | 98% | |||||||||||||||||
| Tripelennamine HCl | + H1 receptor, IC50: 30 μM | 98% | |||||||||||||||||
| Meclizine 2HCl | ✔ | 98% | |||||||||||||||||
| Chlorpheniramine maleate | +++ Histamine H1 receptor, IC50: 12 nM | 99% | |||||||||||||||||
| Diphenhydramine HCl | ✔ | 99% | |||||||||||||||||
| Alcaftadine | ++++ H1 receptor, pKi: 8.5 | ++ H2 receptor, pKi: 7.2 | 99%+ | ||||||||||||||||
| Fexofenadine HCl | ++ Histamine H1 receptor, IC50: 246 nM | 99%+ | |||||||||||||||||
| Bilastine | +++ H1 receptor, Ki: 44.15 nM | 98% | |||||||||||||||||
| Pemirolast potassium | ✔ | 98% | |||||||||||||||||
| Bepotastine besilate | + Histamine H1 receptor, pIC50: 5.7 | 98% | |||||||||||||||||
| Mizolastine | +++ Histamine H1 receptor, IC50: 47 nM | 98% | |||||||||||||||||
| Brompheniramine maleate | ✔ | 98% | |||||||||||||||||
| Carbinoxamine maleate salt | ✔ | 99+% | |||||||||||||||||
| Clemastine fumarate | ++++ Histamine H1 receptor, IC50: 3 nM | 98% | |||||||||||||||||
| Ketotifen fumarate salt | ✔ | 95% | |||||||||||||||||
| Rupatadine Fumarate | ++ Histamine H1 receptor, Ki: 102 nM | PAFR | 98% | ||||||||||||||||
| Famotidine | ✔ | 97% | |||||||||||||||||
| Roxatidine Acetate HCl | + Histamine H2 receptor, IC50: 3.2 μM | 98% | |||||||||||||||||
| Lafutidine | ✔ | 99% | |||||||||||||||||
| Cimetidine | ✔ | 98% | |||||||||||||||||
| Nizatidine | ++++ Histamine H2 receptor, IC50: 0.9 nM | AChE | 98% | ||||||||||||||||
| Ranitidine | ✔ | 96% | |||||||||||||||||
| Betahistine | + Histamine H3 receptor, IC50: 1.9 μM | 99% | |||||||||||||||||
| Ciproxifan maleate | +++ Histamine H3 receptor, IC50: 9.2 nM | 99%+ | |||||||||||||||||
| S 38093 | ++ human H3 receptor, Ki: 1.2 μM rat H3 receptor, Ki: 1.44 μM | 98% | |||||||||||||||||
| JNJ-7777120 | ++++ Histamine H4 receptor, Ki: 4.5 nM | 99% | |||||||||||||||||
| Azelastine HCl | ✔ | 98% | |||||||||||||||||
| Epinastine HCl | ✔ | 99% | |||||||||||||||||
| Levodropropizine | ✔ | 97% | |||||||||||||||||
| Cyproheptadine HCl | ✔ | 98% | |||||||||||||||||
| Hesperetin | ✔ | 97% | |||||||||||||||||
| Olopatadine HCl | ✔ | 98% | |||||||||||||||||
| Mianserin HCl | ✔ | 99+% | |||||||||||||||||
| Buclizine 2HCl | ✔ | 95% | |||||||||||||||||
| Latrepirdine 2HCl | ✔ | GluR | 99% | ||||||||||||||||
| Cetirizine 2HCl | ✔ | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | Latrepirdine is an orally active,and neuroactive antagonist of multiple drug targets, including histamine receptors, GluR, and 5-HT receptors, used as an antihistamine drug. | 
| Concentration | Treated Time | Description | References | |
| Mouse N2a neuroblastoma cells | 500 pM-5 μM | 6 h | To evaluate the effect of Latrepirdine on extracellular Aβ levels. Results showed that Latrepirdine at 500 nM significantly increased extracellular Aβ levels by 64% (p = 0.01). | Mol Neurodegener. 2009 Dec 17;4:51. | 
| ATG5−/− MEFs | 50 μM | 3 h | No change in APP-CTF or p62 accumulation, confirming that the latrepirdine-related stimulation of clearance of APP metabolites and p62 was Atg5-dependent. | Mol Psychiatry. 2013 Aug;18(8):889-97. | 
| WT MEFs | 50 μM | 3 h | Significant decreases in p62 and p-S6K levels, indicating enhanced autophagic activity. | Mol Psychiatry. 2013 Aug;18(8):889-97. | 
| N2a neuroblastoma cells | 500 nM or 50 μM | 3 or 6 h | Significant and dose-dependent increase in LC3-II levels, indicating enhanced autophagosome formation and activity. | Mol Psychiatry. 2013 Aug;18(8):889-97. | 
| HeLa cells | 50 μM | 6 h | Enhanced the number of eGFP-LC3 punctae, indicating that latrepirdine induced formation of autophagosomes. | Mol Psychiatry. 2013 Aug;18(8):889-97. | 
| Yeast strain 2XαSyn | 100 μM | Protected yeast from α-synuclein toxicity by inducing autophagy | Mol Psychiatry. 2013 Aug;18(8):882-8. | |
| SH-SY5Y neurons | 10 nM | 14 days | Reduced levels of α-synuclein, including soluble and insoluble forms, promoting its degradation via autophagy | Mol Psychiatry. 2013 Aug;18(8):882-8. | 
| cerebellar granule neurons (CGNs) | 0.1 nM | 24 h | To investigate the neuroprotective effects of Latrepirdine against glutamate excitotoxicity, results showed significant neuroprotection at 0.1 nM concentration. | Transl Psychiatry. 2013 Oct 22;3(10):e317. | 
| Administration | Dosage | Frequency | Description | References | ||
| Tg2576 mice | Transgenic mice overexpressing Swedish mutant APP | Intraperitoneal injection | 3.5 mg/kg | Single injection, observed for 10 hours | To evaluate the effect of Latrepirdine on brain interstitial fluid Aβ levels. Results showed that a single injection of Latrepirdine significantly increased ISF Aβx-40 levels by 40% (p = 0.01). | Mol Neurodegener. 2009 Dec 17;4:51. | 
| Mice | TgCRND8 transgenic mice | Intraperitoneal injection | 3.5 mg/kg | Once daily for 31 days | Improved learning behavior and reduced accumulation of Aβ42 and α-synuclein. | Mol Psychiatry. 2013 Aug;18(8):889-97. | 
| Wild-type mice | Wild-type mice | Intraperitoneal injection | 3.5 mg/kg | Once daily for 21 days | Enhanced autophagy activity and reduced α-synuclein monomer levels in the brain | Mol Psychiatry. 2013 Aug;18(8):882-8. | 
| Mice | FUS transgenic mouse model | Oral administration via drinking water | 12 mg/kg/day | From the age of 42 days onwards | DF402 delayed the onset and slowed the progression of pathology, increasing animal lifespan by 13%. | CNS Neurosci Ther. 2021 Jul;27(7):765-775 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.55mL 0.51mL 0.25mL | 12.74mL 2.55mL 1.27mL | 25.49mL 5.10mL 2.55mL | |
| CAS号 | 97657-92-6 | 
| 分子式 | C21H27Cl2N3 | 
| 分子量 | 392.37 | 
| SMILES Code | CC1=CC=C(CCN2C3=C(CN(C)CC3)C4=C2C=CC(C)=C4)C=N1.[H]Cl.[H]Cl | 
| MDL No. | MFCD01617545 | 
| 别名 | Dimebolin dihydrochloride; Dimebolin (hydrochloride); Latrepirdine; Dimebon; Latrepirdine dihydrochloride | 
| 运输 | 蓝冰 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, store in freezer, under -20°C | 
| 溶解方案 | DMSO: 5 mg/mL(12.74 mM),配合水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 100 mg/mL(254.86 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1